Tilray Brands (TLRY) Net Income towards Common Stockholders (2017 - 2026)

Tilray Brands (TLRY) posted Net Income towards Common Stockholders of -$25.2 million for Q1 2026, up 42.01% on a QoQ basis from -$43.5 million in Q4 2025, and up 96.82% year-over-year from -$12.8 million in Q1 2025.

Tilray Brands (TLRY) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends

Tilray Brands' Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$25.2 million for Q1 2026.

  • Quarterly Net Income towards Common Stockholders rose 96.82% year-over-year to -$25.2 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$1.5 billion (down 72.77% YoY) and the FY2025 annual result came in at -$2.3 billion, down 1559.72% from the prior year.
  • Net Income towards Common Stockholders was -$25.2 million for Q1 2026 at Tilray Brands, up from -$43.5 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $816.3 million in Q2 2023 and bottomed at -$1.4 billion in Q2 2025.
  • A 5-year average of -$190.7 million and a median of -$55.9 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Peak annual rise in Net Income towards Common Stockholders reached 425.45% in 2023, while the deepest fall reached 2378.71% in 2023.
  • Tilray Brands' Net Income towards Common Stockholders stood at -$85.1 million in 2022, then soared by 45.71% to -$46.2 million in 2023, then tumbled by 84.65% to -$85.3 million in 2024, then soared by 48.98% to -$43.5 million in 2025, then surged by 42.01% to -$25.2 million in 2026.
  • Business Quant data shows TLRY's Net Income towards Common Stockholders at -$25.2 million in Q1 2026, -$43.5 million in Q4 2025, and $1.5 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 370.00 Mn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn 57.00 Mn
10 Tilray Brands 454.65 Mn 394.45 Mn 54.95 Mn -25.23 Mn

Historic Data

Download Data
DateValue
Feb 28, 2026 -25.23 Mn
Nov 30, 2025 -43.51 Mn
Aug 31, 2025 1.51 Mn
May 31, 2025 -1.39 Bn
Feb 28, 2025 -793.53 Mn
Nov 30, 2024 -85.28 Mn
Aug 31, 2024 -34.65 Mn
May 31, 2024 68.04 Mn
Feb 29, 2024 -104.98 Mn
Nov 30, 2023 -46.18 Mn
Aug 31, 2023 -55.86 Mn
May 31, 2023 816.31 Mn
Feb 28, 2023 -1.20 Bn
Nov 30, 2022 -85.06 Mn
Aug 31, 2022 -65.79 Mn
May 31, 2022 -250.82 Mn
Feb 28, 2022 52.48 Mn
Nov 30, 2021 5.80 Mn
Aug 31, 2021 -34.60 Mn
May 31, 2021 345.90 Mn